BIOS Fund II, LP — SEC Form 4 filings
SEC reporting owner CIK 1714576. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-19 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 571,428 shares, $4,499,996 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 59 legs across 8 filings — 440,737 shares, $2,038,001 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 69.
- Largest priced transaction: purchase of 375,000 shares @ $8.00 ($3,000,000) in ACTUATE THERAPEUTICS, INC., filed 2024-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | Director, 10% owner | 4 | 3 legs · 571,428 sh · $4,499,996 | 6 legs · 49,998 sh · $424,983 | 52 |
| Lantern Pharma Inc. (LTRN) | 10% owner | 6 | — | 53 legs · 390,739 sh · $1,613,018 | 6 |
| IN8BIO, INC. | 10% owner | 2 | — | — | 7 |
| COGNITION THERAPEUTICS INC (CGTX) | Director, 10% owner | 3 | — | — | 4 |
Form 4 filings — BIOS Fund II, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund II QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund I QP, LP | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-06-30 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 34,000 @ $0 | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 more | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09 | EDGAR |
| 2025-05-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 more | EDGAR |
| 2025-05-07 | 4 | IN8BIO, INC. jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 1,148,482 (derivative) · Other (J): 574,241 (derivative) · Other (J): 574,241 (derivative) | EDGAR |
| 2024-10-11 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 709,040 (derivative) · Purchase (P): 709,040 (derivative) · Disposition to issuer (D): 574,241 (derivative) · Grant/award (A): 574,241 (derivative) | EDGAR |
| 2024-08-20 | 4/A | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Holdings only — no transactions reported | EDGAR |
| 2024-06-11 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 8,500 @ $0 · Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 930 @ $6.25 · Sale (S): 1,859 @ $6.33 · Sale (S): 6,944 @ $6.25 · Sale (S): 13,888 @ $6.33 · Sale (S): 2,126 @ $6.25 · Sale (S): 4,253 @ $6.33 | EDGAR |
| 2024-02-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 4,649 @ $4.40 · Sale (S): 6,909 @ $4.85 · Sale (S): 1,832 @ $4.87 · Sale (S): 34,731 @ $4.40 · Sale (S): 51,608 @ $4.85 · Sale (S): 13,686 @ $4.87 · +3 more | EDGAR |
| 2024-01-19 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Option exercise/expiry (X): 7,347 @ $3.13 · Sale (S): 5,475 @ $4.20 · Option exercise/expiry (X): 54,873 @ $3.13 · Sale (S): 40,893 @ $4.20 · Option exercise/expiry (X): 16,801 @ $3.13 · Sale (S): 12,521 @ $4.20 · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1714576 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →